sarpogrelate has been researched along with ritanserin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elz, S; Pertz, H | 1 |
| Choi, HS; Jun, DW; Kim, DC; Kim, EK; Kwon, YI; Lee, HL; Lee, KN; Lee, OY; Yoon, BC | 1 |
2 other study(ies) available for sarpogrelate and ritanserin
| Article | Year |
|---|---|
In-vitro pharmacology of sarpogrelate and the enantiomers of its major metabolite: 5-HT2A receptor specificity, stereoselectivity and modulation of ritanserin-induced depression of 5-HT contractions in rat tail artery.
Topics: Allosteric Regulation; Animals; Female; Guinea Pigs; In Vitro Techniques; Male; Rats; Rats, Wistar; Receptors, Serotonin; Ritanserin; Serotonin Antagonists; Stereoisomerism; Succinates; Tail; Vasoconstriction | 1995 |
5-HT2A receptor antagonists inhibit hepatic stellate cell activation and facilitate apoptosis.
Topics: Actins; Animals; Apoptosis; Cell Line; Cell Survival; Collagen Type I; Dose-Response Relationship, Drug; Hepatic Stellate Cells; Humans; Ketanserin; Liver Cirrhosis, Experimental; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Receptor, Serotonin, 5-HT2A; Ritanserin; RNA, Messenger; Serotonin 5-HT2 Receptor Antagonists; Smad2 Protein; Smad3 Protein; Succinates; Thioacetamide; Time Factors; Transforming Growth Factor beta; Wound Healing | 2013 |